Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Inclusion Criteria

• •1. Written informed consent.
• •2. Proven infiltrating breast cancer with distant metastases or inoperable locally advanced disease.
• •3. Positive estrogen receptor (≥ 10% positive nuclei at immunohistochemistry). Progesterone and HER-2 neu receptor have to be known.
• •4. \- Progressive disease during first line hormonal therapy (either tamoxifen or aromatase inhibitor) for metastatic or inoperable locally advanced disease. Simultaneous use of LH-RH analogs is allowed. OR - Recurrence of disease (M1) during adjuvant hormonal therapy (either tamoxifen or aromatase inhibitor).
• •5. No prior chemotherapy for metastatic disease
• •6. Willing and able to participate in Quality of Life investigation -